

Brief Articles

New Pyrrolo[2,1-*f*]purine-2,4-dione and Imidazo[2,1-*f*]purine-2,4-dione Derivatives as Potent and Selective Human A₃ Adenosine Receptor Antagonists

Pier Giovanni Baraldi,^{*,§} Delia Preti,[§] Mojgan Aghazadeh Tabrizi,[§] Francesca Fruttarolo,[§] Romeo Romagnoli,[§] Naser Abdel Zaid,[†] Allan R. Moorman,[‡] Stefania Merighi,[#] Katia Varani,[#] and Pier Andrea Borea[#]

Dipartimento di Scienze Farmaceutiche, and Dipartimento di Medicina Clinica e Sperimentale-Sezione di Farmacologia, Università di Ferrara, 44100 Ferrara Italy, College of Pharmacy, An-Najah National University, Nablus, Palestine, and King Pharmaceutical R & D, 4000 CentreGreen Way, Suite 300 Cary, North Carolina 27513

Received February 10, 2005

Compounds presenting an additional fused ring on the xanthine nucleus have been reported to exhibit antagonistic activity with various levels of affinity and selectivity toward the four adenosine receptors subtypes A₁, A_{2A}, A_{2B}, and A₃. This paper reports synthesis and biological evaluation of new 1-benzyl-3-propyl-1*H*,6*H*-pyrrolo[2,1-*f*]purine-2,4-diones and 1-benzyl-3-propyl-1*H*,8*H*-imidazo[2,1-*f*]purine-2,4-diones, among which we identified potent and selective A₃ adenosine receptors antagonists. In particular, 1-benzyl-7-methyl-3-propyl-1*H*,8*H*-imidazo[2,1-*f*]purine-2,4-dione (**11e**) shows a K_i (hA₃) value from binding assay of 0.8 nM.

Introduction

Adenosine exerts a number of physiological functions through the activation of cell membrane G-protein coupled receptors classified into four different subtypes named A₁, A_{2A}, A_{2B}, and A₃.¹ The A₃ adenosine receptor is able to cause inhibition of forskolin-induced cAMP accumulation, to increase phosphatidylinositol-specific phospholipase C and D activity, and to elevate IP₃ levels and intracellular Ca²⁺ pools.² As a therapeutic target, it is the subject of intensive pharmacological characterization due to its significant involvement in several pathophysiological processes, such as inflammation, neurodegeneration,^{3,4} cardiac and brain ischaemic damage,^{5,6} asthma,⁷ and cancer.⁸

A₃ receptor agonists appear to exert dual and opposite effects, either cytoprotective or cytotoxic, depending on the cell type and on the level of receptor activation.^{9,10} A₃ receptors and their ability to regulate cell survival represent a promising therapeutic target in diseases in which excessive cell death is either undesirable, such as neurodegeneration, or desirable, such as cancer and inflammation.^{11,12} Adenosine acts as a potent regulator of both normal and tumor cell growth.^{13,14} Evidence of high levels of expression of A₃ adenosine receptor subtype has been provided in Jurkat cells,¹⁵ a human leukemia cell line originating from the immune system, in the human melanoma A375 cell line,¹⁶ and in human pancreatic, breast, prostate, colon, lung, and ovarian carcinoma cells.¹⁷ A₃ antagonists seem to synergistically enhance cytotoxic treatment and counter P-glycoprotein

efflux in multidrug resistance.¹⁷ Furthermore, A₃ receptor antagonists may be useful in the treatment of glaucoma.¹⁸

In the past few years, different classes of compounds with nonxanthine structures have been reported to be A₃ adenosine receptor antagonists.^{19–21} In a recent work, the approach based on the annelation of xanthine derivatives for the development of adenosine receptors antagonists has been extensively considered.²² In particular, 1*H*,3*H*-pyrido[2,1-*f*]purine-2,4-diones²³ and imidazo[2,1-*i*]purin-5-ones²⁴ have been claimed as potent A₃ adenosine receptor antagonists. Recently, we reported a series of 1,3-dipropyl-7-aryl/heteroaryl-1*H*,6*H*-pyrrolo[2,1-*f*]purine-2,4-dione derivatives which were conceived as rigid analogues of KF17837, a known A_{2A} adenosine receptor antagonist belonging to the class of styryl xanthines.²⁵ Unfortunately, the synthesized compounds did not show significant affinity for the investigated targets.

The report by Priego et al.²³ about the mentioned 1*H*,3*H*-pyrido[2,1-*f*]purine-2,4-diones highlighted the importance of a benzyl and a propyl moieties at the 1 and 3 positions, respectively. In light of this we thought that the lack of activity of our reported 1,3-dipropyl-pyrrolo[2,1-*f*]purine-2,4-dione derivatives might be partially due to the presence of a propyl chain, instead of the benzyl moiety at the 1 position. We therefore evaluated the effect of the introduction of a benzyl and a propyl at the 1 and 3 position, respectively, in our previous series and in a new series of fused xanthine derivatives. In particular, we performed the synthesis of 1-benzyl-3-propyl-7-aryl/alkyl-1*H*,6*H*-pyrrolo[2,1-*f*]purine-2,4-dione (**7a–d**, Table 1) and 1-benzyl-3-propyl-7-aryl/alkyl-1*H*,8*H*-imidazo[2,1-*f*]purine-2,4-dione (**11a–n**, Table 1). We report the synthesis of these new tricyclic structures and the evaluation of their affinity and activity for the human adenosine A₁, A_{2A}, A_{2B}, and


* To whom correspondence should be addressed. Tel: +39-0532-291293. Fax: +39-0532-291296. E-mail: baraldi@dns.unife.it.

§ Dipartimento di Scienze Farmaceutiche, Università di Ferrara.

Dipartimento di Medicina Clinica e Sperimentale-Sezione di Farmacologia, Università di Ferrara.

† An-Najah National University.

‡ King Pharmaceutical R & D.

Table 1. Structures and Physicochemical Parameters of the Synthesized Compounds


compd	R	R'	mp (°C)	MW	formula	anal.
7a	H	Ph	235	398.46	C ₂₄ H ₂₂ N ₄ O ₂	C, H, N
7b	H	CH ₃	180	336.39	C ₁₉ H ₂₀ N ₄ O ₂	C, H, N
7c	H	CH ₂ CH ₃	148	350.41	C ₂₀ H ₂₂ N ₄ O ₂	C, H, N
7d	CH ₃	CH ₃	114–115	350.41	C ₂₀ H ₂₂ N ₄ O ₂	C, H, N
11a	H	Ph	255	399.45	C ₂₃ H ₂₁ N ₅ O ₂	C, H, N
11b	H	4-OCH ₃ -Ph	257	429.47	C ₂₄ H ₂₃ N ₅ O ₃	C, H, N
11c	H	4-Ph-Ph	272	475.54	C ₂₉ H ₂₅ N ₅ O ₂	C, H, N
11d	H	4-F-Ph	250	417.44	C ₂₃ H ₂₀ FN ₅ O ₂	C, H, N
11e	H	CH ₃	303	337.38	C ₁₈ H ₁₉ N ₅ O ₂	C, H, N
11f	H	CH ₂ CH ₃	285	351.17	C ₁₉ H ₂₁ N ₅ O ₂	C, H, N
11g	H	CH(CH ₃) ₂	128–130	365.43	C ₂₀ H ₂₃ N ₅ O ₂	C, H, N
11h	H	C(CH ₃) ₃	230	379.46	C ₂₁ H ₂₅ N ₅ O ₂	C, H, N
11i	H	cyclopropyl	244–245	363.41	C ₂₀ H ₂₁ N ₅ O ₂	C, H, N
11l	H	cyclohexyl	130–132	405.49	C ₂₃ H ₂₇ N ₅ O ₂	C, H, N
11m	CH ₃	CH ₃	259	351.17	C ₁₉ H ₂₁ N ₅ O ₂	C, H, N
11n	CH ₃	CH ₂ CH ₃	239	365.19	C ₂₀ H ₂₃ N ₅ O ₂	C, H, N

A₃ receptors through radioligand binding assays and cAMP assays.

Results and Discussion


Chemistry. 1-Benzyl-3-propyl-1*H*,6*H*-pyrrolo[2,1-*f*]purine-2,4-dione derivatives (**7a–d**) and 1-benzyl-3-propyl-imidazo[2,1-*f*]purine-2,4-dione derivatives (**11a–**

n) were prepared following the general synthetic strategy depicted in Scheme 1. The 6-amino-1-benzyl-3-propyl-uracil **1** was synthesized starting from 1-benzyl-6-aminouracil according to a known procedure for the alkylation at the N³ position via protection of the amino group at the 6-position as *N*-[(dimethylamino)methylene] derivative.²⁶ Subsequent nitrosation at the 5-position in acetic acid with NaNO₂ furnished compound **2**, and then the reduction of the nitroso group with sodium dithionite²⁷ gave 5,6-diamino-1-benzyl-3-propyl-uracil **3** in good yield.

The synthesis of the final 1-benzyl-3-propyl-1*H*,6*H*-pyrrolo[2,1-*f*]purine-2,4-dione derivatives **7a–d** required the conversion of intermediate **3** into the 3-benzyl-8-hydroxymethyl-1-propyl-3,7-dihydro-purine-2,6-dione **4** by a two-step reaction. Refluxing derivative **3** with glycolic acid, followed by cyclization of the resulting amide intermediate by heating in a solution of aqueous NaOH, afforded the desired product **4**.²⁵ Alkylation at the N⁷-position with the appropriate α -halo-ketone using K₂CO₃ in DMF as solvent provided the 3-benzyl-8-hydroxymethyl-7-(2-oxo-alkyl)-1-propyl-3,7-dihydro-purine-2,6-dione derivatives **5a–d** in good yield. The obtained 7-(2-oxo-alkyl)-8-hydroxymethyl derivatives were converted into the corresponding 8-bromomethyl-purine-2,6-dione intermediates **6a–d** via treatment with PBr₃ in anhydrous benzene.

To obtain the cyclization which furnished the pyrrole ring condensed at the N⁷–C⁸ link of the purinone nucleus, we employed a strategy involving an intramo-

Scheme 1^a



^a Reagents: (i) NaNO₂, CH₃COOH, EtOH, 40 °C, 30 min; (ii) Na₂S₂O₄, H₂O, 85 °C, 30 min; (iii) (a) HOCH₂CO₂H, dioxane, 100 °C, 1 h; (b) NaOH, EtOH/H₂O, reflux, 3 h; (iv) α -halo-ketones, K₂CO₃, DMF, rt, 6–10 h; (v) PBr₃, benzene, rt, 4–6 h; (vi) (a) PPh₃, benzene, reflux, 5 h; (b) CH₃ONa, CH₃OH, 0 °C, 10'; (vii) (a) HCO₂H, reflux, 1 h; (b) NaOH, EtOH/H₂O, reflux, 1 h; (viii) Br₂, CH₃CO₂H, CH₃CO₂Na, 45 °C, 1 h; (ix) liquid ammonia, EtOH, 120 °C, ON.




Figure 1. Inhibitory curves of cAMP accumulation in human A_3 adenosine receptors by adenosine antagonists blocking the effect of 100 nM Cl-IB-MECA.

lecular Wittig reaction between the carbonyl moiety of the introduced N^7 -chain and the bromomethyl function at the 8-position. Thus, we treated the 8-bromomethyl derivatives **6a–d** with triphenylphosphine in benzene, heating the mixture at reflux for 5 h to allow the formation of the intermediate phosphonium salts. The crude material was easily cyclized into the corresponding pyrrolo[2,1-*f*]purine-2,4-diones **7a–d** by treatment with sodium methoxide.²⁵

The 3-benzyl-1-propyl-3,7-dihydro-purine-2,6-dione **8** was obtained by reacting the diamino derivative **3** with formic acid²⁸ according to the same procedure followed for preparation of compound **4**. Bromination at the 8-position with Br_2 and sodium acetate in acetic acid at 60 °C for about 1 h led to formation of the key 8-bromo-intermediate **9** in excellent yield. Alkylation at the N^7 -position with different α -halo-ketones under the same conditions employed for the synthesis of **5a–d** supplied 7-(2-oxo-alkyl)-1-propyl-3,7-dihydro-purine-2,6-dione derivatives **10a–n**. Treatment of these intermediates with liquid ammonia in a sealed tube at 120 °C overnight in ethanol effected, at first, the substitution of the bromine at the 8-position followed by the in situ cyclization of the amino group with the N^7 carbonyl function to give the desired 1-benzyl-3-propyl-1*H*,8*H*-imidazo[2,1-*f*]purine-2,4-dione derivatives **11a–n**.

Biological Evaluation and Structure-Affinity Relationships. All the synthesized compounds were evaluated in radioligand binding assays to determine

their affinities for human A_1 , A_{2A} , and A_3 adenosine receptors. Potency of the compounds versus hA_{2B} adenosine receptors were studied, evaluating their capability to inhibit (100 nM) NECA-stimulated cAMP production. Basal and NECA stimulation of cAMP levels were 15 ± 2 and 80 ± 9 pmoles cAMP/ 10^6 cells, respectively. NECA was able to stimulate cAMP levels in hA_{2B} CHO cells with an EC_{50} value of 145 ± 15 nM. Moreover, the compounds showing high affinity to hA_3 receptors were also studied through cAMP experiments performed in hA_3 CHO cells evaluating their capability to block, in the presence of forskolin 10 μ M, the inhibitory effect mediated by (100 nM)-Cl-IB-MECA (Figure 1). Basal, forskolin stimulation, and Cl-IB-MECA inhibition of cAMP levels were 14 ± 2 , 75 ± 8 , and 40 ± 5 pmoles cAMP/ 10^6 cells, respectively. Cl-IB-MECA was able to inhibit forskolin stimulated cAMP levels with an IC_{50} value of 8.7 ± 0.9 nM. Affinity data for A_1 , A_{2A} and A_3 receptors, expressed as K_i values, and IC_{50} values derived from the cAMP assay carried out for hA_{2B} subtypes, are listed in Table 2.

In the reported series of compounds we evaluated the effect of different heterocycles fused on the N_7 – C_8 positions of the xanthine nucleus. The fundamental feature of these molecules lies in their practically complete selectivity in binding A_3 receptor versus A_1 , A_{2A} and A_3 subtypes, as reflected by the notable K_i (hA_1 - hA_{2A}/hA_3) and IC_{50} (hA_{2B})/ K_i (hA_3) ratios (Table 2). The K_i values related to the interaction with the adenosine A_3 receptor are strictly dependent on the nature of the substituents at the 7-position of the tricyclic structures while the ability to discriminate between the different AR subtypes is not generally affected by such structural modification. The synthesized compounds include both 7-(4-substituted-aryl)-pyrrolo/imidazo[2,1-*f*]purine-2,4-dione and 7-(cyclo)alkyl-pyrrolo/imidazo[2,1-*f*]purine-2,4-dione derivatives.

Among the examined tricycles, the imidazo[2,1-*f*]purine-2,4-dione derivatives **11a**, **11e**, **11f**, and **11m** were 2- to 10-fold more active than the corresponding substituted-pyrrolo[2,1-*f*]purine-2,4-dione derivatives **7a–d** toward the adenosine A_3 receptor subtype. Both series had K_i values in the low nanomolar range ($K_i = 0.8$ –200 nM). This indicates a possible involvement of

Table 2. Binding and Functional Parameters of Synthesized 1*H*,6*H*-Pyrrolo[2,1-*f*]purine-2,4-dione Derivatives (**7a–d**) and Imidazo[2,1-*f*]purine-2,4-dione Derivatives (**11a–n**) Toward hA_1 , hA_{2A} , hA_{2B} , and hA_3 Adenosine Receptors

compd	hA_1^a	hA_{2A}^b	hA_{2B}^c	hA_3^d	hA_1/hA_3	hA_{2A}/hA_3	hA_{2B}/hA_3
7a	>1000	>1000	–	200 (134–297)	>5	>5	–
7b	>1000	>1000	400 (323–496)	8.0 (7.1–9.1)	>125	>125	50
7c	>1000	>1000	>1000	3.5 (2.7–4.4)	>290	>290	>290
7d	>1000	>1000	>1000	80 (63–100)	>13	>13	>13
11a	>1000	>1000	–	115 (89–150)	>9	>9	–
11b	>1000	>1000	–	55 (28–104)	>18	>18	–
11c	>1000	>1000	–	>1000	–	–	–
11d	>1000	>1000	–	22 (19–26)	>45	>45	–
11e	>1000	>1000	>1000	0.8 (0.6–0.9)	>1250	>1250	>1250
11f	>1000	>1000	>1000	15 (9–27)	>67	>67	>67
11g	460 (424–498)	>1000	>1000	31 (25–38)	>15	>32	>32
11h	>1000	>1000	>1000	99 (77–129)	>10	>10	>10
11i	350 (299–411)	>1000	>1000	23 (18–29)	15	>44	>44
11l	>1000	>1000	>1000	555 (467–660)	>2	>2	>2
11m	>1000	>1000	>1000	36 (31–43)	>28	>28	>28
11n	>1000	>1000	>1000	60 (53–69)	>17	>17	>17

^a Displacement of specific [³H]-DPCPX binding to human A_1 receptors expressed in CHO cells (K_i , nM). ^b Displacement of specific [³H]-ZM 241385 binding to human A_{2A} receptors expressed in CHO cells (K_i , nM). ^c cAMP assay in CHO cells expressing hA_{2B} receptors (IC_{50} , nM). ^d Displacement of specific [³H]-MRE3008F20 binding to human A_3 receptors expressed in CHO cells (K_i , nM).

the N⁸-position in the interaction of the molecules with the receptor, suggesting an opportunity to establish a hydrogen bond.

Among the 7-aryl-substituted series, it was observed that substitution at the 4-position of the phenyl ring with a methoxy function or especially with the small electron-withdrawing fluorine atom, which is also able to form hydrogen bonds, produces an increase in affinity, while the introduction of a *p*-phenyl group leads to the total loss of affinity. This indicates that the presence of a large aromatic and lipophilic moiety, such as the biphenyl, at the 7-position of the corresponding tricyclic derivative establishes repulsive interactions with the receptor.

We then decided to evaluate the effect of replacing the phenyl ring at the 7-position of compounds **7a** and **11a–d** with various (cyclo)alkyl chains. Compounds **7b–d** and **11e–l** contain at the 7-position alkyl chains with different length such as -methyl (**7b** and **11e**), -ethyl (**7c** and **11f**), branched alkyl chains such as -isobutyl (**11g**), -*tert*-butyl (**11h**), and cycloalkyl chains such as -cyclopropyl (**11i**) and -cyclohexyl (**11l**). The best results were obtained with the introduction of small linear alkyl chains, in particular a methyl group (**11e**, $K_i(\text{hA}_3) = 0.8 \text{ nM}$ with a surprising selectivity pattern versus the other AR subtypes). Longer chains or branching led to a loss of activity (**11g** $K_i(\text{hA}_3) = 99 \text{ nM}$ and **11l** $K_i(\text{hA}_3) = 555 \text{ nM}$), supporting the observation with the 7-biphenyl derivative (**11c**), which indicates that a sterically demanding, lipophilic moiety at the 7-position would be detrimental to binding. The synthesis of compounds **7d** and **11m,n** permitted us to estimate the effect of the introduction of an additional methyl group at the 6-position of the tricyclic derivatives. In all the examples, this kind of structural modification decreased the affinity of the molecules for the receptor binding site, inducing a significant increase of the related $K_i(\text{hA}_3)$ values (**7d** 10-fold less active than **7b**, **11m** 45-fold less active than **11e**, **11n** 4-fold less active than **11f**). However, modification of this side of the molecule did not seem to affect the selectivity versus A₁, A_{2A}, and A_{2B} receptors.

Conclusions

In conclusion the present study can be considered an innovative contribution to the previously reported²² approach based on annelation of xanthine derivatives. Some of the newly reported imidazo[2,1-*f*]purine-2,4-dione and pyrrolo[2,1-*f*]purine-2,4-dione derivatives represent, to the best of our knowledge, the most potent and selective hA₃ adenosine receptor antagonists containing a xanthine nucleus. In particular 1-benzyl-7-methyl-3-propyl-1*H*,8*H*-imidazo[2,1-*f*]purine-2,4-dione (**11e**) shows a subnanomolar affinity toward the desired receptor target with a noteworthy selectivity versus the other adenosine receptors subtypes ($K_i(\text{hA}_3) = 0.8 \text{ nM}$, $K_i(\text{hA}_1/\text{hA}_3) = 3163$, $K_i(\text{hA}_{2A}/\text{hA}_3) > 6250$, $\text{IC}_{50}(\text{hA}_{2B})/K_i(\text{hA}_3) = 2570$). These data are even more surprising when compared with the binding profile of MRE3008F20,²⁹ a potent A₃ adenosine receptor antagonists belonging to the family of pyrazolo[4,3-*e*]-1,2,4-triazolo[1,5-*c*]pyrimidines ($K_i(\text{hA}_3) = 0.85 \text{ nM}$, $K_i(\text{hA}_1/\text{hA}_3) = 1294$, $K_i(\text{hA}_{2A}/\text{hA}_3) = 165$, $K_i(\text{hA}_{2B}/\text{hA}_3) = 2471$). From the selectivity pattern, it is apparent that com-

pound **11e** represents a significant improvement over MRE3008F20, in particular with regard to the significant increase of selectivity toward adenosine A_{2A} subtype.

Interestingly, a notable concordance between binding and functional experiments performed with the hA₃ receptor has been revealed. Among the examined compounds, the molecules showing the best affinities for the hA₃ adenosine receptor have also proved to have very high potency in functional assays (Figure 1). In particular, derivative **11e** can be considered the most potent compound, exhibiting an IC₅₀ value of 5 nM.

Experimental Section

General Procedure for Preparation of 1-Benzyl-3-propyl-1*H*,6*H*-pyrrolo[2,1-*f*]purine-2,4-dione Derivatives (7a–d**, Intramolecular Wittig Reaction).** A solution of the corresponding bromide **6a–d** (0.42 mmol) and PPh₃ (0.46 mmol) in anhydrous benzene (5 mL) was refluxed for 5 h. After this time, the resulting mixture was concentrated to half-volume and the precipitates collected by filtration. The intermediate phosphonium salts (0.26 mmol) were then added to an ice-cooled and stirred solution of sodium methoxide (0.29 mmol) in anhydrous methanol (5 mL). The reaction was stirred at 0 °C for 10 min, the solvent was evaporated, and the products were purified by column chromatography on silica gel eluting with the appropriate mixture of light petroleum–EtOAc (6:4 for **7a**, 1:1 for **7b–d**).

General Procedure for Preparation of 1-Benzyl-3-propyl-1*H*,8*H*-imidazo[2,1-*f*]purine-2,4-dione Derivatives (11a–n**).** A solution of the appropriate 7-(2-oxo-alkyl)-3,7-dihydro-purine-2,6-dione derivatives **10a–n** (0.4 mmol) in EtOH (4 mL) was cooled at –40 °C. Liquid ammonia (3–4 mL) was then added to the mixture. The mixture was heated in a sealed tube overnight at 100–120 °C. The reaction was finally allowed to cool at room temperature, and then the solvent and the excess of ammonia were evaporated to obtain a residue that was suspended with water and extracted with EtOAc (3 × 25 mL). The organic phase was dried with anhydrous sodium sulfate, and the solvent was evaporated to give a residue, which was purified by column chromatography on silica gel, eluting with the appropriate mixture of light petroleum–EtOAc.

Acknowledgment. We thank King Pharmaceutical R & D 4000 Centre Green Way, Suite 300 Cary, NC 27513, for financial support. We also thank Prof. Karl-Norbert Klotz for cDNA encoding the human adenosine receptors.

Supporting Information Available: Detailed experimental procedures for the synthesis and the biological assays of the reported compounds, C, H, N analytical data, ¹H NMR data. This material is available free of charge via Internet at <http://pubs.acs.org>.

References

- (1) Fredholm, B. B.; Arslan, G.; Halldner, L.; Kull, B.; Schulte, G.; Wasserman, W. Structure and function of adenosine receptors and their genes. *Naunyn-Schmied. Arch. Pharm.* **2000**, *362*, 364–374.
- (2) Fredholm, B. B.; Ijzerman, A. P.; Jacobson, K. A.; Klotz, K.-N.; Linden, J. Nomenclature and classification of adenosine receptors. *Pharm. Rev.* **2001**, *53*, 527–552.
- (3) Jacobson, K. A.; Kim, H. O.; Siddiqui, S. M.; Olah, M. E.; Stiles, G. L.; Von Lubitz, D. K. J. E. A₃ adenosine receptors: design of selective ligands and therapeutic prospects. *Drugs Future.* **1995**, *20*, 689–699.
- (4) Kohno, Y.; Ji, X. D.; Mawhorter, S. D.; Koshiba, M.; Jacobson, K. A. Activation of A₃ adenosine receptors on human eosinophils elevates intracellular calcium. *Blood* **1996**, *88*, 3569–3574.
- (5) Jacobson, K. A. Adenosine A₃ receptors: Novel ligands and paradoxical effects. *Trends. Pharmacol. Sci.* **1998**, *19*, 184–191.

- (6) Von Lubitz, D. K. J. E.; Lin, R. C. S.; Popik, P.; Carter, M. F.; Jacobson, K. A. Adenosine A₃ receptor stimulation and cerebral ischemia. *Eur. J. Pharmacol.* **1994**, *263*, 59–67.
- (7) Jacobson, K. A.; Moro, S.; Kim, Y. C.; Li, A. H. A₃ adenosine receptors: Protective vs damaging effects identified using novel agonists and antagonists. *Drug. Dev. Res.* **1998**, *45*, 113–124.
- (8) Fishman, P.; Bar-Yehuda, S.; Barer, F.; Ohana, G. A₃ adenosine receptors: new targets for cancer therapy and chemoprotection. *Drug. Dev. Res.* **2000**, *50*, 101–117.
- (9) Liang, B. T.; Jacobson, K. A. A physiological role of the adenosine A₃ receptor: sustained cardioprotection. *Proc. Natl. Acad. Sci. U.S.A.* **1998**, *95*, 6995–6999.
- (10) Yao, Y.; Sei, Y.; Abbracchio, M. P.; Jiang, J. L.; Kim, Y. C.; Jacobson, K. A. Adenosine A₃ receptor agonists protect HL60 and U937 cells from apoptosis induced by A₃ antagonists. *Biochem. Biophys. Res. Commun.* **1997**, *232*–317.
- (11) Baraldi, P. G.; Borea, P. A. New potent and selective human adenosine A₃ receptor antagonists. *Trends. Pharm. Sci.* **2000**, *21*, 456–459.
- (12) Merighi, S.; Mirandola, P.; Varani, K.; Gessi, S.; Leung, E.; Baraldi, P. G.; Tabrizi, M. A.; Borea, P. A. A glance at adenosine receptors: novel target for antitumor therapy. *Pharmacol. Ther.* **2003**, *100(1)*, 31–48.
- (13) Gessi, S.; Varani, K.; Merighi, S.; Cattabriga, E.; Avitabile, A.; Gavioli, R.; Fortini, C.; Leung, E.; MacLennan, S.; Borea, P. A. Expression of A₃ adenosine receptors in human lymphocytes: up-regulation in T cell activation. *Mol. Pharmacol.* **2004**, *65*, 711–719.
- (14) Ohana, G.; Bar-yehuda S.; Barer, F.; Fishman, P. Differential Effect of adenosine on tumor and normal cell growth: focus on the A₃ adenosine receptor. *J. Cell. Phys.* **2001**, *186*, 19–23.
- (15) Gessi, S.; Varani, K.; Merighi, S.; Morelli, A.; Ferrari, D.; Leung, E.; Baraldi, P. G.; Spallato, G.; Borea, P. A. Pharmacological and biochemical characterization of A₃ adenosine receptors in Jurkat T cells. *Br. J. Pharmacol.* **2001**, *134*, 116–126.
- (16) Merighi, S.; Varani, K.; Gessi, S.; Cattabriga, E.; Iannotta, V.; Uloglou, C.; Leung, E.; Borea, P. A. Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. *Br. J. Pharmacol.* **2001**, *134*, 1215–1226.
- (17) Borea, P. A.; Baraldi, P. G.; Chen, S. F.; Leung, E. Enhancing treatment of MDR cancer with adenosine A₃ antagonists. PCT Int. Appl. WO 2004000224, 2003.
- (18) Avila, M. Y.; Stone, R. A.; Civan, M. M. Knockout of A₃ adenosine receptors reduces mouse intraocular pressure. *Invest. Ophthalmol. Vis. Sci.* **2002**, *43*, 3021–3026.
- (19) Baraldi, P. G.; Tabrizi, M. A.; Fruttarolo, F.; Bovero, A.; Avitabile, B.; Preti, D.; Romagnoli, R.; Merighi, S.; Gessi, S.; Varani, K.; Borea, P. A. Recent Developments in the Field of A₃ Adenosine Receptor Antagonists. *Drug. Dev. Res.* **2003**, *58*, 315–329.
- (20) Muller, C. E. Medicinal Chemistry of Adenosine A₃ Receptor Ligands. *Curr. Top. Med. Chem.* **2003**, *3*, 445–462.
- (21) Baraldi, P. G.; Cacciari, B.; Moro, S.; Spallato, G.; Pastorin, G.; Da Ros, T.; Klotz, K. N.; Varani, K.; Gessi, S.; Borea, P. A. Synthesis, biological activity and molecular modelling investigation of new pyrazolo[4,3-*e*]-1,2,4-triazolo[1,5-*c*]pyrimidine derivatives as human A₃ adenosine receptor antagonists. *J. Med. Chem.* **2002**, *45*, 770–780.
- (22) Drabczyńska, A.; Schumacher, B.; Müller, C. E.; Karolak-Wojciechowska, J.; Michalak, B.; Pékala, E.; Kieæ-Kononowicz, K. Impact of the aryl substituent kind and distance from pyrimido[2,1-*f*]purindiones on the adenosine receptor selectivity and antagonistic properties. *Eur. J. Med. Chem.* **2003**, *38*, 397–402.
- (23) Priego, E. M.; von Frijtag Drabbe K. J.; Ijzerman, A. P.; Camarasa, M.-J.; Pérez-Pérez, M.-J. Pyrido[2,1-*f*]purine-2,4-dione derivatives as a novel class of highly potent human A₃ adenosine receptor antagonists. *J. Med. Chem.* **2002**, *45*, 3337–3344.
- (24) Müller, C. E.; Thotand, M.; Qurishi, R.; Diekmann, M.; Jacobson, K. A.; Padgett, W. L.; Daly, J. W. Imidazo[2,1-*i*]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A_{2A}- and A₃-adenosine receptor antagonists. *J. Med. Chem.* **2002**, *45*, 3440–3450.
- (25) Baraldi, P. G.; Abdel, Z. N.; Fruttarolo, F.; Tabrizi, A. M.; Nuñez, M.; Spalluto, G.; Romagnoli, R. A synthetic approach for the preparation of rigid analogues of 1,3-dipropyl-7-methyl-8-aryl/heteroarylstyryl xanthine. *Synthesis* **2001**, *5*, 773–777.
- (26) Priego, E. M.; Camarasa, M. J.; Pérez-Pérez, M. J. Efficient synthesis of *N*-3-substituted 6-aminouracil derivatives via *N*⁶-[(dimethylamino)methylene] protection. *Synthesis* **2001**, *3*, 478–482.
- (27) Holschbach, M. H.; Fein, T.; Krummeich, C.; Lewis, R. G.; Wutz, W.; Schwabe, U.; Unterlugauer, D.; Olsson, R. A. A1 Adenosine Receptor Antagonists as Ligands for Positron Emission Tomography (PET) and Single-Photon Emission Tomography (SPET). *J. Med. Chem.* **1998**, *41*, 555–563.
- (28) Kramer, G. L.; Garst, J. E.; Mitchel, S. S.; Wells, J. N. Selective inhibition of cyclic nucleotide phosphodiesterases by analogues of 1-methyl-3-isobutylxanthine. *Biochemistry* **1977**, *16*, 3316–3321.
- (29) Varani, K.; Merighi, S.; Gessi, S.; Klotz, K. N.; Leung, E.; Baraldi, P. G.; Cacciari, B.; Romagnoli, R.; Spallato, G.; Borea, P. A. [³H]-MRE 3008-F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A₃ adenosine receptors. *Mol. Pharmacol.* **2000**, *57*, 968–975.

JM058008C